2023
DOI: 10.3389/fcell.2023.1200466
|View full text |Cite
|
Sign up to set email alerts
|

The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer

Abstract: Urologic cancers such as kidney, bladder, prostate, and uroepithelial cancers have recently become a considerable global health burden, and the response to immunotherapy is limited due to immune escape and immune resistance. Therefore, it is crucial to find appropriate and effective combination therapies to improve the sensitivity of patients to immunotherapy. DNA damage repair inhibitors can enhance the immunogenicity of tumor cells by increasing tumor mutational burden and neoantigen expression, activating i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 155 publications
(197 reference statements)
0
4
0
Order By: Relevance
“…PARP inhibition promote the reduction of myeloid-derived suppressor cells (MDSCs) and immunosuppression-related regulatory T cells (T-regs) in tumor tissue and also relieves the shift of tumor-associated macrophages in the anti-inflammatory M2 type, reprogramming macrophages toward an anti-tumor phenotype. 84 , 85 After PARPi administration, CD4+/CD8+ T cells and natural killer cells are recruited at tumor sites, APCs activate effector T cells and release large amounts of pro-inflammatory cytokines, including IL-2, IFNγ, and TNF-α [ Figure 4(b) ]. 85 …”
Section: Parpi In Combinations With Icis and The Role Of Immune Micro...mentioning
confidence: 99%
See 2 more Smart Citations
“…PARP inhibition promote the reduction of myeloid-derived suppressor cells (MDSCs) and immunosuppression-related regulatory T cells (T-regs) in tumor tissue and also relieves the shift of tumor-associated macrophages in the anti-inflammatory M2 type, reprogramming macrophages toward an anti-tumor phenotype. 84 , 85 After PARPi administration, CD4+/CD8+ T cells and natural killer cells are recruited at tumor sites, APCs activate effector T cells and release large amounts of pro-inflammatory cytokines, including IL-2, IFNγ, and TNF-α [ Figure 4(b) ]. 85 …”
Section: Parpi In Combinations With Icis and The Role Of Immune Micro...mentioning
confidence: 99%
“… 84 , 85 After PARPi administration, CD4+/CD8+ T cells and natural killer cells are recruited at tumor sites, APCs activate effector T cells and release large amounts of pro-inflammatory cytokines, including IL-2, IFNγ, and TNF-α [ Figure 4(b) ]. 85 …”
Section: Parpi In Combinations With Icis and The Role Of Immune Micro...mentioning
confidence: 99%
See 1 more Smart Citation
“…For example, combination of immune checkpoint inhibitors (ICIs) with angiogenesis inhibitors (AGIs) shows synergistic antitumour effects, but also a higher risk of cardiovascular adverse events than treatments with ICIs alone ( 1 ). As well, combining ICIs with DNA damage repair inhibitors (DDRIs) in the treatment of urologic cancers greatly increases the risk of toxicity and side effects ( 2 ). In pediatric patients affected by primary CNS or PNS tumours, MEK inhibitor (MEKI) (trametinib)- induced cardiotoxicity combined with the prothrombotic properties of an immunomodulatory agent (lenalidomide) was observed to lead to significant thromboembolic events, requiring termination of this combination regimen ( 3 ).…”
Section: Introductionmentioning
confidence: 99%